| Name | Title | Contact Details |
|---|
At Mallinckrodt, we use strategic vision and employee-driven momentum to pursue a powerful mission: Managing Complexity. Improving Lives. As a specialty pharmaceuticals leader, we develop, manufacture, market and distribute specialty pharmaceuticals and therapies. Within our areas of focus, we provide treatments to underserved patient populations within neurology, rheumatology, nephrology, pulmonology, and ophthalmology. At Mallinckrodt, we use strategic vision and employee-driven momentum to pursue a powerful mission: Managing Complexity. Improving Lives. As a specialty pharmaceuticals leader, we develop, manufacture, market and distribute specialty pharmaceuticals and therapies. Within our areas of focus, we provide treatments to underserved patient populations within neurology, rheumatology, nephrology, pulmonology, and ophthalmology. Our expertise also extends into acute and critical care hospital products, as well as our broad portfolio of generic prescription medicines, and active pharmaceutical ingredients. Together, we`re helping shape the future of the specialty pharmaceuticals industry by leveraging the values our founders instilled nearly 150 years ago – quality, integrity and service. Mallinckrodt Pharmaceuticals provides equal employment opportunities (EEO) to all employees and applicants for employment without regard to race, color, religion, gender, sexual orientation, gender identity, national origin, age, disability, veteran status, or genetics. In addition to federal law requirements, Mallinckrodt Pharmaceuticals complies with applicable state and local laws governing nondiscrimination in employment in every location in which the company has facilities. This policy applies to all terms and conditions of employment, including recruiting, hiring, placement, promotion, termination, layoff, recall, transfer, leaves of absence, compensation and training.
Envision Wellness WNY Behavioral Health has been providing counseling and treatment services in WNY for decades to all persons who have requested guidance.
Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus` lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).
MyDental360 - Know what matters. Find what works. Powered by Kulzer The information you want on the subjects that affect your everyday work. We cover them from every angle—in a concise view delivered right to your inbox. Your Benefits • Busine...
#Mentalhealth causes invisible wounds. Find strength, hope and how you can help heal others. Family Service of Roanoke Valley. https://t.co/57fyeIBthG